Loading...
EGFR gene copy number by FISH may predict outcome of necitumumab in squamous lung carcinomas: analysis from the SQUIRE study.
Genova, C Socinski, M Hozak, R Mi, G Kurek, R Shahidi, J Paz-Ares, L Thatcher, Nick Rivard, C Varella-Garcia, M
Genova, C
Socinski, M
Hozak, R
Mi, G
Kurek, R
Shahidi, J
Paz-Ares, L
Thatcher, Nick
Rivard, C
Varella-Garcia, M
Citations
Altmetric:
Abstract
Necitumumab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR). In the SQUIRE trial, the addition of necitumumab to chemotherapy in squamous cell lung cancer (SCC) significantly improved overall survival (OS) (HR=0.84); in a post-hoc analysis, EGFR copy number gain determined by fluorescence in situ hybridization (FISH) showed a trend towards improved OS (HR=0.70) and progression-free survival (PFS) (HR=0.71) with the addition of necitumumab. We present the analysis of granular EGFR-FISH data from SQUIRE to examine the potential predictive role of high polysomy and gene amplification as both were included in the "FISH-positive" category.
Description
Date
2017-11-17
Publisher
Collections
Keywords
Type
Article
Citation
EGFR gene copy number by FISH may predict outcome of necitumumab in squamous lung carcinomas: analysis from the SQUIRE study. 2017, J Thorac Oncol